Labopharm is notified of Actavis' filing for a generic Oleptro

11/14/2010 | Reuters

Actavis has notified Labopharm of its FDA filing for a generic version of Oleptro, the latter's once-daily treatment for depression. Labopharm, which is reviewing the formal notice, has market exclusivity for the drug through Feb. 2, 2013.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX